Search results
Author(s):
Heng Shee Kim
,
Hou Tee Lu
Added:
1 year ago
Author(s):
Chak-yu So
,
Leo Kar Lok Lai
,
Ling Na Wong
,
et al
Added:
1 year ago
Author(s):
Varun Sundaram
Added:
1 month ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Author(s):
Wanwarang Wongcharoen
,
Rungroj Krittayaphong
,
Wacin Buddhari
,
et al
Added:
2 months ago
Women As One CLIMB® 2024 Skills Training Program
Video Series
Henryk Dreger
Job title: Interventional Cardiologist
Author
Author(s):
Added:
1 week ago
ADA 2025 - We are joined by Dr Alice Cheng (University of Toronto, Toronto, CA) to discuss the clinical implications of STRIDE (NCT04560998). The placebo-controlled study investigated whether semaglutide with standard-of-care treatment has an effect on walking ability in patients with PAD and T2D. The primary outcome measure was the change in maximum walking distance on a constant load treadmill…
View more
Author(s):
Nisa Nadhira Mohd Nazi
,
Raja Ezman Raja Shariff
,
Mohd Rahal Yusoff
,
et al
Added:
1 year ago
Karim Al-Azizi
Job title: Interventional Cardiologist and Structural Heart Disease Specialist
Author
Author(s):
Mirvat Alasnag
Added:
1 year ago
EuroPCR 2024 - We are joined by Dr Mirvat Alasnag (King Fahd Armed Forces Hospital, SA) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.Trials covered in detail include:IRONMAN IIDESyne BDS PlusNOTION IILANDMARKPINNACLERecorded onsite at EuroPCR 2024, Paris by William Cadden and Dan Brent
View more